Xiaodong Wang, Sironax co-founder and chairman

BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-re­lat­ed biotech, with ARCH jump­ing in

Five years af­ter form­ing and with more than $100 mil­lion al­ready in­vest­ed in the com­pa­ny, a biotech from BeiGene co-founder Xi­aodong Wang is back with an­oth­er whop­ping in­vest­ment, this time at $200 mil­lion.

Siron­ax dis­closed the Se­ries B on Tues­day, say­ing the funds will bankroll stud­ies of drugs for age-re­lat­ed de­gen­er­a­tive dis­eases that in­clude “reg­u­lat­ed cell death, neu­ro­pro­tec­tive path­ways and neu­roin­flam­ma­tion.” Al­ready in the clin­ic are two re­cep­tor-in­ter­act­ing ser­ine/thre­o­nine-pro­tein ki­nase 1 (RIPK1) in­hibitors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.